Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib


ÇETİN B., IŞIK GÖNÜL İ., GÜMÜŞAY Ö., AFŞAR B., Bilgetekin I., ÖZET A., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.2, pp.408-413, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.4103/jcrt.jcrt_372_18
  • Journal Name: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.408-413
  • Süleyman Demirel University Affiliated: Yes

Abstract

Objective: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival. Materials and Methods: The expression of ezrin was measured by immunohistochemistry in 80 patients with ccRCC treated by first-line sunitinib between January 2007 and June 2012. Kaplan-Meier curves and log-rank tests were used for analysis of progression-free survival and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on the survival. Results: In multivariate analysis, liver metastasis (P = 0.018; hazard ratio [HR]: 3.707 (1.257-10.931) and overexpression of ezrin (P = 0.006; HR: 2.993 (1.373-6.523 95% confidence interval) were remained significant factors influencing OS. Overexpression of ezrin in the patients who had progressed in the first 3 months was higher than in the patients who had progressed after 3 months (P = 0.003). The median OS was longer in patients with low levels of ezrin expression (27 months) compared to patients overexpressing ezrin (12 months) (P = 0.001). Conclusion: This is the first study in the literature showing that ezrin status is related with prognosis in patients with metastatic ccRCC.